LeonaBio, Inc.
19.99%
1,859,322
1620463
04746L203
Jan 15, 2026
Jan 16, 2026, 04:46 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | Investment Adviser | 19.99% | 1,859,322 | 0 | 1,859,322 |
| Joseph Edelman | Individual | 19.99% | 1,859,322 | 0 | 1,859,322 |
| Perceptive Life Sciences Master Fund, Ltd. | CO | 16.40% | 1,529,566 | 0 | 1,529,566 |
| Perceptive Xontogeny Venture Fund II, LP | Partnership | 3.50% | 329,756 | 0 | 329,756 |
Disclosure Items (4)
Common Stock, $0.0001 par value
LeonaBio, Inc.
18706 North Creek Parkway, Bothell, WA, 98011
Item 5 of the Schedule 13D is amended and supplemented as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on an aggregate of 9,300,434 shares of Common Stock outstanding, consisting of (i) 3,943,887 shares of Common Stock outstanding as of November 5, 2025, as disclosed by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 6, 2025, and (ii) 5,356,547 shares of Common Stock issued in the Private Placement.
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. Mr. Edelman holds vested stock options to purchase shares of Common Stock in connection with his service as a director of the Issuer; however, such options are not included in the number of shares beneficially owned by Mr. Edelman or the other Reporting Persons because Mr. Edelman agreed on January 13, 2026 that such options cannot be exercised by Mr. Edelman without providing notice to the Issuer of at least 61 days to the extent that such exercise would result in Mr. Edelman or the other Reporting Persons beneficially owning more than 19.99% of the outstanding shares of Common Stock of the Issuer. In addition, pursuant to the terms of the warrants and pre-funded warrants held by the Master Fund and PXV II, the Reporting Persons may not exercise such warrants or pre-funded warrants to the extent that such exercise would result in beneficial ownership in excess of 19.99% of the outstanding shares of Common Stock of the Issuer. As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their warrants or pre-funded warrants.
Except as set forth in this Amendment No. 6, none of the Reporting Persons has effected any transaction in shares of Common Stock since the filing of Amendment No. 5 to the Schedule 13D, filed with the SEC on December 23, 2025.
Item 6 of the Schedule 13D is amended and supplemented as follows: The information set forth in Item 5(b) of this Amendment No. 6 is incorporated by reference into this Item 6.